Sharechat Logo

Genesis float well supported

By Phil Boeyen, ShareChat Business News Editor

Thursday 14th September 2000

Text too small?
Auckland-based biotechnology company, Genesis Research and Development Corporation Limited, has closed its $34.5 million IPO with strong support from retail and institutional investors.

Genesis offered 5.75 million shares at $6.00. The company says it is particularly pleased with the high level of interest from large Australian institutional investors.

Shareholder statements will be mailed on September 19 and trading on the NZSE and ASX will start on Friday, 22 September under the code GEN.

Genesis says most of the money raised will go towards its research and development activities

These include clinical development of immune therapies for psoriasis and asthma, expansion into eczema, the development of Genesis' forestry genomic platform in a relatively new venture with ArborGen LLC, and building new databases and technology to secure a foundation in agriculture and horticulture.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Genesis Research directors quit due to lack of funds & communication
Genesis Research has ‘lack of funds’, seeks legal advice on future
Genesis Research halted from trading pending statement
Genesis Research calls off proposed merger with Mariposa Health
Kupe earnings bolster Genesis 1H profit by 125%
Genesis Research plans "reverse takeover"
Genesis Research director Graham Chin resigns in wake of rift with UBNZ
Tekapo purchase knocks $73m off Genesis bottom line
UBNZ gets in deeper with Genesis Research
Genesis Energy beats forecast

IRG See IRG research reports